Clinical trial
Post-marketing Evaluation of Reactions Following Receipt of Recommended…
NCT00304265 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00304265 |
|---|---|
| Title | Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine |
| Official title | Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at… |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pertussis, Diphtheria, Tetanus, Poliomyelitis |
| Intervention type | Biological |
| Interventions | COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®) |
| Enrollment | 215 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Mar 17, 2006 |
| Last update posted | Apr 14, 2016 |
| Countries | Germany |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: